Core Viewpoint - Duori Pharmaceutical reported a significant decline in both revenue and net profit for the third quarter and the first three quarters of the year, indicating potential challenges in its financial performance and market position [1] Financial Performance Summary - The company's revenue for the third quarter was 30.4254 million yuan, a year-on-year decrease of 39.32% [1] - The net profit for the third quarter was a loss of 37.2241 million yuan, representing a decline of 169.69% [1] - For the first three quarters, the total revenue was 137 million yuan, down 43.07% year-on-year [1] - The net profit for the first three quarters showed a loss of 79.7277 million yuan, which is a decrease of 27.23% compared to the previous year [1]
多瑞医药：第三季度净利润亏损3722.41万元，下降169.69%